Lipella to collaborate in anticipation of forthcoming Investigational New Drug (IND) application LP-10 is a promising potential treatment for hemorrhagic cystitis that has received Orphan Drug Designation from the FDA Lipella has successfully completed a Phase 2a clinical trial evaluating LP-10 PITTSBURGH, April 17, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc.… Read More..

- PodcastOne Repays $1 Million of Its Debt Convertible at $3 and Expects to Repay an Additional $1 Million to $2 Million - Extends Record Date to April 20, 2023 - Increases Dividend of PodcastOne Shares to LiveOne’s Shareholders of Record to Between 12% and 16% - LiveOne’s Buyback Exceeds… Read More..

PRINCETON, N.J., April 5, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Adopted Names (USAN) Council has approved the use… Read More..